






Cancer cell adhesive interactions – more than just physical attraction 
 
Selectins promote tumor metastasis 
 
 
Heinz Läubli1,2 and Lubor Borsig1 
 
1Institute of Physiology, University of Zürich, 8057 Zürich, Switzerland 
and Zürich Center for Integrative Human Physiology  





Lubor Borsig  
:  
Institute of Physiology University of Zürich 
Winterthurerstrasse 190  
CH-8057 Zürich, Switzerland  
Phone: +41 44 635-5134  
Fax:     +41 44 635-6814  
Email: lborsig@access.uzh.ch 
 




Cancer metastasis is facilitated by cell-cell interactions between cancer cells and 
endothelial cells in distant tissues. In addition, cancer cell interactions with platelets and 
leukocytes contribute to cancer cell adhesion, extravasation, and the establishment of 
metastatic lesions. Selectins are carbohydrate-binding molecules that bind to sialylated, 
fucosylated glycan structures, and are found on endothelial cells, platelets and 
leukocytes. There are three members of the selectin family: P-selectin expressed on 
activated platelets and endothelial cells, L-selectin present on leukocytes and E-selectin 
expressed on activated endothelial cells. Besides the accepted roles of selectins in 
physiological processes, such as inflammation, immune response and hemostasis, there 
is accumulating evidence for the potential of selectins to contribute to a number of 
pathophysiological processes, including cancer metastasis. Cancer cell interactions with 
selectins are possible due to a frequent presence of carbohydrate determinants – 
selectin ligands on the cell surface of tumor cells from various type of cancer. The 
degree of selectin ligand expression by cancer cells is well correlated with metastasis 
and poor prognosis for cancer patients. Initial adhesion events of cancer cells facilitated 
by selectins result in activation of integrins, release of chemokines and are possibly 
associated with the formation of permissive metastatic microenvironment. While E-
selectin has been evaluated as one of the initiating adhesion events during metastasis, it 
is becoming apparent that P-selectin and L-selectin mediated interactions significantly 
contribute to this process as well. In this review we discuss the current evidence for 




Hematogenous metastasis of cancer consists of several steps enabling cancer cells to 
intravasate, to survive in the blood circulation and to adhere to the vessels, eventually 
extravasating and establishing new metastatic lesions. Interactions of intravascular 
cancer cells with blood constituents (platelets, leukocytes) can modulate their capacity 
to adhere to endothelium in distant organs thereby facilitating metastasis. This process 
of cancer cell adhesion and seeding to specific vascular beds appears to be a rate 
limiting step in cancer metastasis. It is well accepted that malignant transformation is 
associated with abnormal glycosylation resulting in presentation of altered carbohydrate 
structures. Enhanced expression of sialyl Lewisx and sialyl Lewisa structures is 
frequently associated with cancer progression and poor prognosis [1]. At the same time, 
these carbohydrates are recognized selectin ligands. Selectins are vascular cell 
adhesion molecules involved in interactions of leukocytes, platelets and endothelium. 
Due to the temporal and spatial presence of selectins during hematogeneous 
dissemination and early organ colonization, interactions with carbohydrate ligands on 
cancer cells can be expected. Studies from several laboratories suggest that metastatic 
cancer cells exploit similar mechanisms as used by leukocytes for adhesion and 
extravasation through endothelium that may contribute to metastasis [2, 3]. Recent 
evidence also indicates that selectin-mediated interactions may contribute to formation 
of a permissive microenvironment for metastasis [4]. 
 
Selectins – vascular cell adhesion molecules 
Selectins were identified to be the key adhesion molecules that mediate leukocyte 
trafficking and hemostasis, soon after their cloning and characterization [5-7]. 
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Subsequently, selectins were implicated in many human diseases including cancer [3, 7-
10]. Selectins are type-I transmembrane glycoproteins consisting of an extracellular C-
type lectin domain, an EGF domain, two to nine consensus repeats, a transmembrane 
domain and a cytoplasmic tail [5]. L-selectin is constitutively expressed on all myeloid 
cells, on naïve T-cells and some activated memory T-cells [5, 11]. Activation of 
leukocytes leads to a rapid loss of L-selectin from their cell surfaces due to a proteolytic 
cleavage [7].  P-selectin is constitutively expressed in endothelial cells of the lung and 
the choroid plexus, megakaryocytes, thrombocytes and is stored within Weibel-Pallade 
bodies of endothelial cells or alpha-granules of platelets, respectively [5, 6]. P-selectin is 
rapidly presented on the surface of activated endothelial cells or platelets by means of 
exocytosis of storage granules and their fusion with the cell membrane [12-14]. E-
selectin is expressed exclusively by endothelial cells, mainly in response to local 
activation [5]. Constitutive expression of E-selectin has been detected in the skin and 
parts of bone marrow microvasculature [15]. In most vessels de novo synthesis and 
expression of E-selectin can be induced within two to six hours in response to 
inflammatory stimuli (e.g. TNF-α and IL-1β) or disturbed blood flow [5, 16]. Expression of 
P- and E-selectin is tightly regulated during homeostasis, thereby ensuring spatial and 
temporal adhesion/recruitment of leukocytes. However, E-selectin may remain up-
regulated in the endothelium in areas of chronic inflammation [17, 18].  
 
Selectin ligands 
Selectin-based adhesion is mediated by heterotypic interactions of their C-type lectin 
domain with glycan-bearing ligands. Functional selectin ligands require post-
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translational modification of scaffold proteins by glycosyltransferases and 
sulfotransferases [5, 19-21]. The minimal recognition motif for all selectins is the sialyl-
Lewisx sLex and its isomer sialyl-Lewisa (sLea) tetrasaccharide that is synthesized by 
α1,3-Fucosyltransferases IV or VII, α2,3-Sialyltransferases, β1,4-Galactosyltranferases 
and N-Acetyl-Glucosaminyltransferases [5, 21, 22]. Efficient selectin-binding to 
carbohydrates usually requires a glycoprotein scaffold that facilitates the presentation of 
several selectin ligands in clusters [5, 20]. P-selectin glycoprotein ligand-1 (PSGL-1) is 
the best characterized ligand, which is concentrated on the tips of microvilli on leukocyte 
cell surfaces. All three selectins bind to PSGL-1, while potent binding of P- and L-
selectin to PSGL-1 is facilitated by additional sulfation of the amino-terminal part of the 
protein [5, 6]. Although leukocytes express a number of different selectin ligands, e.g. 
CD44 [23], or E-selectin ligand-1 (ESL-1) [24], PSGL-1 is the main physiological ligand 
for P-selectin [5, 6]. L-selectin mediates the trafficking of leukocytes, in particular 
lymphocytes through binding to peripheral node addressins (PNAds) that are endothelial 
glycoproteins [21]. E-selectin binds to a number of ligands, including PSGL-1, ESL-1, 
CD44, CD43, β2-integrins, and L-selectin [5, 25-29]. Mucins are major carriers of altered 
glycosylation that occur during progression of epithelial cancers - carcinomas. Mucins 
are high-molecular-weight molecules containing a protein core substituted with a large 
number of O-linked glycan structures [9, 30]. Major alterations are an enhanced 
expression of sLex/a, or Tn and sialyl-Tn antigen structures on mucins [31]. Carcinoma 
mucins expressing sLex/a structures are major selectin ligands on cancer cells. In 
addition to mucins, several other selectin ligands on cancer cells have been described 
including CD24, CD44, death-receptor 3, ESL-1 and PSGL-1 [32-35]. However, the in 
vivo relevance of these ligands remains to be determined [24]. Finally, P- and L-selectin, 
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but not E-selectin can bind to sulfated glycans including heparin, heparin sulfate, 
fucoidan and sulfated glycolipids in a calcium-independent manner [20, 36]. The large 
variety of different carbohydrate structures recognized by selectins indicates that the 
lectin domain of selectins recognize a certain carbohydrate “patch” that can be 
generated in different ways [20]. 
 
Roles of selectins health and disease 
The characterization of selectin and selectin ligand deficient mice has provided 
information about the physiological functions of selectins in inflammation, immune 
response, wound repair and hemostasis [37-41]. These findings have been further 
confirmed in mice deficient in selectin ligands, e.g. FucT-VII, Core 2 
glucosaminyltransferase, or PSGL-1 [42-45]. Extravasation of leukocytes comprises 
sequential steps including tethering of leukocytes on endothelial cells, fast and slow 
rolling, firm adhesion and trans- or para-endothelial migration [46, 47]. Selectins mediate 
the initial tethering and are critically involved in the transition from fast to slow rolling 
before leukocytes firmly adhere to endothelial cells [5, 6, 47]. Transition from fast to slow 
rolling requires activation of integrins that is in part supported by selectin or PSGL-1 
outside-in signaling [48, 49]. Given the central role in leukocyte extravasation and 
trafficking, selectins are involved in innate and adaptive immune responses and this 
topic is extensively covered elsewhere [5, 21, 47]. Importantly, cell homing studies in 
mice showed that adhesion of leukocytes differs between organs and types of 
inflammation [7, 50].  
P-selectin on platelets is involved in thrombus formation during hemostasis [51, 52]. The 
procoagulant activity of P-selectin is mainly explained by its role in the formation of 
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leukocyte derived microparticles containing tissue factor, the key inducer of the extrinsic 
coagulation cascade [52, 53]. Moreover, PSGL-1 on platelets could enhance 
interactions between them and mediate binding of platelets to P- and E-selectin on 
activated endothelial cells, thus influencing hemostasis [54]. 
Acute systemic inflammatory responses to infectious or toxic stimulants and trauma are 
uncontrolled inflammatory, life threatening events that can lead to SIRS (systemic 
inflammatory response syndrome), sepsis and eventually to multi-organ failure [55]. 
Selectins are involved in acute organ damage during sepsis by mediating the 
recruitment of myeloid cells [56]. In different disease models, P- or E-selectin deficient 
mice are protected from acute inflammation and tissue damage [57, 58]. L-selectin 
deficiency also decreases leukocyte recruitment to sites of acute inflammation [59]. 
Inhibition of E- or P-selectin by antibodies or heparin showed significantly reduced 
disseminated intravascular coagulation and mortality in an experimental septic shock 
model [60].  
Chronic inflammation plays a key role in atherosclerosis, the main cause of morbidity 
and mortality in developed nations [61]. Recruitment of inflammatory cells during 
progression of the atherosclerotic lesion is partially selectin dependent [61]. The 
absence of P-selectin reduces atherosclerotic lesions due to reduced monocyte 
recruitment [62]. Monocyte recruitment during atherogenesis is facilitated by P-selectin 
on activated platelets adherent on the endothelium [63]. P-selectin mediated rolling of 
platelets on activated endothelial cells further supports progression of atherosclerotic 
lesions [64]. Atherosclerosis is partly decreased by the absence of E-selectin [65]. 





Selectin interactions beyond cell adhesion 
Selectin-mediated interactions facilitate not only cell adhesion, but may also participate 
in signal transduction, thereby affecting cell migration and activation of other adhesion 
molecules including integrins [47-49, 67]. Selectin engagement can trigger signals in 
both the selectin-expressing and the ligand-expressing cells [68, 69]. While the signaling 
pathways for selectins are just being revealed, leukocyte extravasation represents the 
best described selectin-initiated signaling pathway [47]. Binding of L-selectin can 
activate leukocytes and affect the cytoskeleton trough interactions between the 
cytoplasmic tail of L-selectin with α-actinin, ezrin/radixin/moesin (ERM) family proteins, 
calmodulin, increase of intracellular calcium and induction of the p38 mitogen-activated 
kinase pathway [49, 70-74]. L-selectin mediated activation of neutrophils can lead to the 
production of reactive oxygen species, TNF-α, interleukin-8 and integrins, including 
CD11b [49, 75]. Monocytes can be activated by the engagement of PSGL-1 on their 
surfaces by P-selectin [76]. P-selectin binding to PSGL-1 induces signaling that 
activates integrins through the Src kinase family, Nef-associated factor 1 and 
phosphoinositide-3-OH-kinases [48, 77, 78]. The cytoplasmic tail of PSGL-1 also 
interacts via ERM proteins with the cytoskeleton and the spleen tyrosine kinase (SYK) 
that may transmit signals [79, 80]. There is also evidence that the engagement of P-
selectin transmits signals to endothelial cells and platelets, while the mechanism 
remains unclear [49]. E-selectin binding to PSGL-1 activates β2 integrins through the 
SYK and Src kinase pathway that is required for initiation of neutrophil slow rolling [81]. 
E-selectin itself can transduce signals into endothelial cells through p38 and p42/p44 
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MAPK pathway [69]. Finally, selectin binding to cell-surface-bound mucins may also 
transmit signals into cancer cells during cancer progression, e.g. by enhancing growth 
factor receptor signaling [30, 82].  
 
Selectins and cancer progression 
How cancer cells metastasize is still not completely understood. Experimental evidence 
and observational clinical studies suggest that cancer cell seeding requires specific 
interactions with the local microenvironment that lead to tumor cell adhesion or 
mechanical arrest, survival, extravasation and outgrowth in target organs. As described 
above, the majority of cancer cells, carcinoma cells in particular, express elevated levels 
of selectin ligands that are associated with poor prognosis [reviewed in 1, 10, 31]. 
Selectin-mediated interactions of cancer cell binding to and activation of leukocytes, 
platelets and endothelial cells provide a mechanistic explanation for this poor prognosis 
(Figure 1) [83-85]. Cell-cell interactions with leukocytes, platelets and endothelium 
appear to be critical for metastatic progression. Parallels between selectin-mediated 
leukocyte recruitment and extravasation during inflammation, and adhesion/arrest and 
extravasation of cancer cells during metastasis has been observed in different models 
(Figure 1) [2, 8, 9]. Moreover, recent findings suggest that selectins mainly support 
tumor progression via the cooption of inflammatory pathways [4]. Finally, selectins are 
strongly involved in coagulation abnormalities often observed in cancer patients, further 






E-selectin during cancer progression 
E-selectin is a major adhesion receptor on endothelial cells for leukocytes and has been 
repeatedly shown to support metastasis in vivo [88, 89]. E-selectin has been 
investigated as a mediator of the process by which cancer cells adhere/arrest in the 
microvasculature during metastasis [3, 90, 91]. The presence of E-selectin ligands on 
cancer cells correlates with enhanced adhesion to activated endothelium [92-95]. E-
selectin ligands on cancer cells have been found to be mostly mucins [96], yet several 
unique E-selectin ligands have been recently identified on cancer cells, including dead 
receptor-3 and a specific CD44 glycoform [33, 34]. E-selectin binding of death receptor 3 
or other ligands on cancer cells has been shown to increase survival during metastasis 
[34, 97]. Recent work provides evidence that E-selectin binding to cancer cells may alter 
the gene expression profile of cancer cells [97]. Furthermore, E-selectin has been 
shown to regulate endothelial transmigration through activation of p38 and ERK AP 
kinases [98, 99]. Since distinct E-selectin ligands on neutrophils have been shown to 
induce different reactions [24], it can be expected that the nature of E-selectin ligands 
presented on cancer cells may induce specific processes both in endothelial cells as 
well as in cancer cells.  
E-selectin is expressed on activated endothelial cells and has been shown to be 
upregulated during metastatic colonization of the liver [88, 89]. Downregulation of E-
selectin expression or inhibition of E-selectin function resulted in attenuation of 
experimental liver metastasis. In a transgenic mouse model over-expressing E-selectin 
in the liver, metastases were redirected to this organ, thus confirming the role of E-
selectin in this process [100]. In an experimental metastasis model where mice were 
injected with IL-1, co-injection of cancer cells with soluble E-selectin probe led to a 
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reduction of metastasis in the lungs [93]. However, induced E-selectin expression by a 
high cytokine dose does not reflect the natural process of metastatic lung colonization. 
We recently demonstrated that E-selectin is disposable in a model of experimental lung 
metastasis [101]. These findings probably reflect organ specific differences in the 
colonization process and different requirements for selectin-mediated interactions 
depending on the primary tumor and the metastatic organ. Nevertheless, in vivo 
evidence for cancer cell rolling on activated endothelium mediated through E-selectin 
that leads to metastatic colonization requires further investigation. 
 
P-selectin during cancer progression 
The close “relationship” of circulating cancer cells with platelets is one of the factors 
contributing to cancer progression [14, 102-104]. Substantial evidence indicates that 
platelets interact with circulating cancer cells, thereby creating tumor microemboli that 
may facilitate arrest in distant organs and subsequently promote interactions with 
endothelium [102, 103]. Evidence that platelets support metastasis initially came from 
models of experimentally induced thrombocytopenia [105, 106]. Likewise, platelet-
deficient mice lacking Nf-E2 showed reduced metastasis [107]. The underlying 
mechanism for the initiation of platelet-cancer cell thrombi formation remains to be 
defined. However, experimental evidence strongly indicates that platelet P-selectin 
contributes to the thrombi formation and aids colonization of cancer cells in the lungs 
[84, 108]. Platelet aggregates on cancer cells lodged in the vasculature was virtually 
absent in P-selectin deficient mice and was associated with a limited initial seeding of 
cancer cells to the lungs [108]. Platelets were shown to bind to cancer cells through 
carcinoma cell surface mucins in a P-selectin dependent manner. Removal of cell 
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surface mucins from cancer cells prior to intravenous injection resulted in attenuation of 
metastasis [108]. Bone marrow transplantation experiments in P-selectin deficient mice 
have shown that endothelial P-selectin also contributes to metastasis [109]. 
Furthermore, inhibition of P-selectin-mediated interactions of platelets with cancer cell 
ligands by heparin treatment attenuates cancer metastasis in mice [108, 109].   
Patients suffering from advanced cancer are at high risk for thromboembolic events, a 
finding initially described by Trousseau [87]. The particular association between 
thrombotic diathesis and mucinous carcinomas led to hypothesis that mucins, carrying 
selectin ligands, trigger this syndrome. Intravenous injection of purified carcinoma 
mucins led to a rapid generation of platelet-rich microthrombi [87]. Interestingly, in P-
selectin but also L-selectin deficient mice the microthrombi generation was markedly 
diminished, indicating the involvement of platelet P-selectin and leukocytes in thrombotic 
events accompanying cancer progression.  
 
L-selectin during cancer progression 
Initial studies focused on the potential role of L-selectin on tumor cells by homing to L-
selectin ligand expressing tissues [110, 111]. Transgenic ectopic expression of L-
selectin in a spontaneous mouse carcinoma model facilitated lymph node metastasis 
[110]. However, naturally occurring L-selectin on a B-cell lymphoma cell line was not 
associated with enhanced lymph node metastasis [111]. 
Inflammation is a key component of the tumor microenvironment and leukocytes have 
been shown to promote both primary tumor growth as well as metastatic dissemination 
[112, 113]. Leukocyte responses to cancer are not unique, and have many parallels with 
the inflammatory response to infection and during wound healing [112, 114]. 
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Contribution of leukocytes to metastasis largely depends on spatial and temporal 
stimulation that is defined by the microenvironment and cancer cells [112, 114, 115]. L-
selectin-mediated leukocyte recruitment to locally activated endothelial cells is one 
possible means that may be exploited by cancer cells. The contribution of L-selectin to 
metastasis was analyzed in L-selectin deficient mice [83, 85]. The absence of L-selectin 
led to attenuation of metastasis. This finding actively implicates leukocytes to the 
process of metastasis, since L-selectin expression is restricted to leukocytes [83]. L-
selectin mediated recruitment of leukocytes to tumor emboli was found to occur 
subsequent to P-selectin-mediated platelet-cancer cell complex formation [85, 101]. 
These observations suggest that L-selectin mediates recruitment and adhesion of 
leukocytes within the microenvironment of metastasizing cancer cells, either with the 
tumor thrombus itself or with the adjacent endothelium. Concomitantly, enhanced 
expression of L-selectin ligands around the cancer cell embolus correlated with the 
recruitment of leukocytes to the intravascular cancer cells, indicative of locally activated 
endothelium [85]. Leukocytes associated with cancer cells in the vasculature were 
identified as CD11b positive cells of myeloid origin (monocytes, neutrophils, or 
precursors). Further studies have shown that monocytes can directly increase 
transendothelial migration of cancer cells through L-selectin mediated interactions (L.B., 
manuscript in preparation). Thus, leukocytes may assist cancer cells in breaching the 







Selectins promote metastasis by shaping the metastatic niche 
There is sufficient experimental evidence that selectins mainly promote metastasis by 
facilitating heterotypic interactions between cancer cells and blood components 
including endothelial cells (Figure 2) [3, 10].  
After entering the bloodstream directly or via lymphatics, cancer cells are transported to 
distant organs, where they are arrested within the microvasculature (Figure 2a) [117, 
118].  Platelet-cancer cell association and the formation of a tumor embolus during the 
intravascular phase is thought to be a key step during metastatic dissemination and 
colonization (Figure 2b) [14, 102-104, 119]. Cancer patients with advanced, metastatic 
disease have increased serum levels of markers of platelet activation and a higher 
percentage of activated platelets, probably indicating platelet activation during 
metastatic spread [104, 120]. Whether cancer cell-platelet interactions are directly 
initiated after intravasation or after microvascular arrest of cancer cells remains unclear. 
In experimental metastasis models, formation of tumor emboli within the pulmonary 
microvasculature is observed rapidly after the injection of cancer cells (Figure 2b) [105, 
108]. Nevertheless, the proof for significant tumor cell emboli formation in cancer 
patients is hampered by pre-analytical treatment of blood samples with a considerable 
chance of introducing artifacts. Since the isolation methods for circulating cancer cells 
are becoming more standardized [121, 122], the isolation of circulating tumor emboli 
may become feasible. Primary activation of platelets by cancer cells in vivo is not yet 
completely understood, but abundant evidence indicates the involvement of tissue factor 
induced formation of thrombin and signaling through protease activated receptors (PAR) 
[123, 124]. In mice with platelets lacking PAR4, activation of platelets was strongly 
reduced and metastasis diminished [107]. Besides minor roles for GPIIb/IIIa and 
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GPIb/IX in aggregation of platelets on cancer cells [105, 125-127], tumor emboli 
formation mainly depends on P-selectin mediated interactions [108]. Platelets and tumor 
emboli formation may promote metastasis by various means including protection from 
immune-mediated clearance of cancer cells through NK-cells [128, 129], enhancement 
of microvascular arrest [127], cancer cell invasion through secretion of proteases [130, 
131], as well as enhanced angiogenesis and growth through the release of various 
cytokines such as PDGF and VEGF and bioactive lipids like lysophosphatidic acid  [14, 
104, 132]. We recently provided evidence that platelets promote metastatic colonization 
by supporting the formation of an inflammatory niche within the lung microvasculature 
[4]. P-selectin mediated interactions between cancer cells, platelets and neutrophils led 
to a local inflammatory activation of endothelial cells [4]. Platelets can support 
inflammatory activation by the release of cytokines and chemokines [13]. It is 
conceivable that the formation of a tumor embolus through P-selectin leads to locally 
increased levels of platelet cytokines and chemokines. Platelet aggregation and tumor 
emboli formation may additionally occlude microvessels and thus lead to hypoxic areas, 
promoting a local inflammatory reaction. Moreover, platelet aggregation on cancer cells 
induces and is perpetuated by the coagulation cascade, finally resulting in increased 
levels of thrombin and fibrin deposition [119]. Thrombin itself can activate cancer cells 
and the local endothelium through PAR signaling [119, 124], thereby potentially 
enhancing local inflammation. 
The inflammatory microenvironment that is generated by tumor-embolus formation 
activates the adjacent endothelium and recruitment of leukocytes (Figure 2c). Markers of 
endothelial cell activation and inflammation are up-regulated during the first hours after 
microvascular arrest of cancer cells in models of experimental liver and lung metastasis 
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[88, 101, 133]. Endothelial cell activation markers such as soluble E-selectin and ICAM-
1 detected in plasma are elevated in cancer patients with advanced disease [134]. 
Reduction of endothelial cell activation in experimental models was associated with 
decreased metastasis [135, 136]. Activated endothelial cells further support local 
inflammatory activation and formation of a metastatic niche, mainly by mediating the 
recruitment of leukocytes. Recruitment and activation of inflammatory cells, in particular 
myeloid cells are associated with enhanced metastatic colonization [4, 85, 116, 137, 
138]. Selectin mediated interactions facilitate the recruitment of leukocytes to the 
metastatic microenvironment [4, 83, 85]. L-selectin mediated interactions were 
demonstrated to be essential for the recruitment of neutrophils and monocytes in an 
experimental model of metastasis [83, 85]. Interactions of L-selectin with a yet 
unidentified FucT VII dependent ligand on activated endothelial cells contribute to 
recruitment of leukocytes [85]. Furthermore, selectin dependent interactions between 
cancer cells, platelets and neutrophils led to the up-regulation of endothelial CCL5 and 
subsequent recruitment of monocytes to the metastatic microenvironment [4]. Inhibition 
of CCL5 and subsequently reduced monocyte recruitment attenuated metastasis [4]. 
Myeloid cells may support metastatic colonization by local immune-suppression, cancer 
cell survival, invasion and extravasation (Figure 2d) [114, 139, 140]. Monocytes and 
descendant macrophages were recently shown to facilitate lung colonization by 
enhancing extravasation [116]. L-selectin dependent recruitment of monocytes can 
directly increase vascular permeability and transendothelial migration of cancer cells 
(L.B., manuscript in preparation). E-selectin has also been shown to contribute to the 
extravasation process [91].  
17 
 
Many studies linking selectins to the metastatic process have utilized experimental 
metastasis models. A limitation of direct intravascular injection of cancer cells is the 
absence of a pre-metastatic niche. The pre-metastatic niche was first identified in mouse 
models of spontaneous metastasis and has subsequently been shown to be present in 
cancer patients [141-143]. Myeloid precursor cells are mobilized and recruited to specific 
locations by the primary tumor in an endocrine dependent manner [141-143].  Thereby 
myeloid cells can shape the local microenvironment in order to make it permissive for 
arriving cancer cells [141-143]. The role of selectins in the formation of the pre-
metastatic niche, however, remains largely elusive and necessitates further studies and 
validation in human cancer patients.  
 
Selectin-inhibitors as anti-metastatic therapeutics 
The expression and involvement of selectins during inflammation, immune response and 
cancer led to the rationale that inhibitors of selectins could be used as anti-inflammatory, 
immune-modulating, and anti-cancer agents and several types of inhibitors were 
developed over the past years [7, 144]. Selectin inhibitors can be divided into glycan-
based molecules, small molecules including glycomimetics, soluble forms of ligands and 
antibodies either targeting selectins or their ligands. The first tested inhibitor was a 
sialyl-Lewisx tetrasaccharide that could target all selectins. However the low affinity, high 
production costs and unfavorable pharmacokinetics made it not suitable for further 
development [7]. Glycometabolic inhibitors have been developed that indirectly reduce 
the production of selectin ligands by inhibition of relevant glycosyltransferases, in 
particular O-glycosylation of mucins and fucosyltransferases [144, 145]. Treatment of 
cancer cells with a disaccharide-based inhibitor that serves as a decoy for the glycan 
18 
 
synthesis led to reduction of cancer cell-associated sLex structures and subsequently to 
attenuation of metastasis [146, 147]. A recombinant soluble form of PSGL-1 was shown 
to inhibit the rolling of leukocytes in vivo, and prevents inflammation in different modes 
of inflammation [144, 148, 149]. However, clinical trials were discontinued partly due to 
high production costs [7]. Small molecules or glycomimetics including bimosiamose 
(TBC-1269), cylexin (CY1503) and efomycine M that inhibit selectins were tested in 
models of ischemia-reperfusion injury, psoriasis and asthma and to some extent 
evaluated in clinical trials [144, 150-152]. Selectin blocking antibodies that successfully 
passed preclinical evaluation were examined in patients with psoriasis, reperfusion 
injury or cerebral ischemia with no or only minimal clinical effect [151].  
Heparin is a glycosaminoglycan exclusively expressed and stored in mast cells and 
consists of N- and O-sulfated alternating galactosamine/glucosamine and glucoronic 
acid/iduronic acid moieties [153]. Heparin and fractionated low molecular weight 
heparins are clinically used for their anti-coagulant activity via antithrombin III and the 
pentasaccharide sequence for this effect is well characterized [153]. Moreover, 
unfractionated heparin and some clinically used low molecular heparins bind to P- and 
L-selectins and inhibit their function [108, 154, 155]. However, not all low molecular 
weight heparins show inhibitory activity on selectins, indicating that selectin binding to 
heparin requires a specific properties independent of anticoagulant activity [155, 156]. 
Indeed, chemically modified heparins with minimal anticoagulant activity but retained its 
selectin inhibitory activity efficiently attenuated experimental metastasis [10, 108, 157-
159]. Besides inhibition of selectins, heparins probably improve survival by influencing 
heparanase activity, growth factor signaling and inhibition of different cell adhesion 
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molecules including integrins [36]. In clinical trials, heparins are associated with a better 
survival of patients [160].  
Selectins are mainly implicated in hematogenous metastasis during the intravascular 
phase of cancer cells. Based on the above described mechanism, heparin inhibition of 
P- and L-selectin should be applied immediately following initial cancer diagnosis until a 
period of time (e.g. a few weeks) after surgical removal of the primary tumor [161]. 
Moreover, the demonstrated implication of selectins in the metastatic process warrants 
the application of selectin inhibitors to patients with a local tumor stage in order to 
prevent dissemination. Since selectins are crucial for homeostasis, it is unlikely that 
prolonged treatment will be feasible. Based on the proposed treatment window 
encompassing about two months, the specific inhibition of one or two selectins should 
be well tollerated. Interestingly, there is precedence for the prolonged inhibition of P-
selectin. Therapeutic doses of heparin efficiently inhibit P-selectin and also L-selectin, 
therefore cancer patients treated with heparin as an anticoagulant inadvertently 
achieved significant P-selectin inhibition [154]. Clinical trials are currently ongoing that 
evaluate the use of low molecular weight heparins after surgery of localized tumors in 
addition to adjuvant systemic treatment (e.g. NCT00475098, NCT00967148). Finally, 
modified heparins with a selective effect on selectin inhibition or other inhibitors of 
selectins require further examination in preclinical models and testing in early clinical 
trials. 
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Figure 1 Selectin-mediated interaction in health and during cancer metastasis. 
a) Selectins mediate initial interactions leading to adhesion of leukocytes and platelets to 
sites of locally activated endothelium often at sites of acute or chronic inflammation.  
b) Potential interactions that occur between selectins and cancer cells during 
hematogeneous metastasis. All interactions have been shown to occur in vivo. While 
multiple interactions are possible, the temporal and spatial presence of selectins 
determines their contribution to metastasis. Potential role of selectins in metastasis: 1 – 
L-selectin mediates the recruitment of leukocytes to cancer cells, and L-selectin-
mediated activation of leukocytes may be expected. Whether L-selectin mediates a 
direct contact between leukocytes and cancer cells remains to be determined. 2 – 
Platelet-cancer cell interactions are primarily mediated by P-selectin, and platelet 
aggregates. Thereby platelets protect cancer cells from the innate immune system and 
contribute to the means by which cancer cells adhere to and/or mechanistically arrest in 
the microvasculature. 3 – Adhesion of cancer cells to activated endothelium has been 
well described primarily in vitro. E- and P-selectin involvement in cancer cell adhesion to 
endothelium indicates a pro-metastatic function for activated endothelium in vivo. The 
mechanism leading to specific expression of E-selectin in distant organs remains to be 
defined. 
 
Figure 2 Selectins support tissue colonization by mediating heterotypic 




a) Cancer cells from primary lesions reach blood vessels either directly or through lymph 
vessels. Intravasated cancer cells circulate until they become arrested in the 
microvasculature of distant organs. b) During circulation or after microvascular arrest, a 
tumor embolus is formed by P-selectin mediated interactions of tumor cells (TC) with 
platelets (minutes-hours after intravasation). The micrograph shows MC-38 tumor cells 
(grey) arrested in the pulmonary microvasculature 30 minutes after intravenous injection 
of tumor cells. Aggregates of platelets (red, CD41) are observed around the tumor cells.  
Nuclei are blue. EC, endothelial cells.  c) Tumor embolus formation and intravascular 
arrest leads to the subsequent inflammatory activation of the metastatic 
microenvironment, including activation of endothelial cells (aEC) and recruitment of 
myeloid cells (MC) including neutrophils and monocytes (hours-days). Leukocyte 
recruitment depends partially on L-selectin and the expression of FucT VII dependent 
selectin ligands on activated endothelial cells. Moreover, endothelial P-selectin and E-
selectin could be implicated in leukocyte recruitment. Selectin-mediated interactions 
contribute to local chemokine production that enhances inflammatory activation of the 
microenvironment. The micrograph shows myeloid cells (CD11b, green and Gr1, red 
positive cells) within the pulmonary microenvironment of intravenously injected MC-38 
tumor cells (grey) during early lung colonization. Nuclei are blue. d) Inflammatory 
activation of the metastatic microenvironment partially mediated by selectins generates 
a metastatic niche, wherein tumor cells can survive, extravasate, proliferate and 
eventually form new metastatic lesions. The micrograph shows the growing edge of a 
metastatic lesion; tumor cells (green), F4/80 positive cells (red), nuclei (blue). From 
metastatic lesions, cancer cells can again intravasate and disseminate to other organs 
or the primary lesion [162]. 
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